FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313409546> ?p ?o ?g. }

• W4313409546 endingPage "459" @default.
• W4313409546 startingPage "446" @default.
• W4313409546 abstract "The COVID-19 mortality is associated with an increase in interleukin-6 (IL-6) levels. Levilimab is an anti–IL-6 receptor antibody with proven clinical efficacy in patients with severe COVID-19. The aim of the study was to assess the association of COVID-19 severity and levilimab effectiveness with IL-6 levels and to explore the potential for using levilimab in other conditions accompanied by cytokine release syndrome. Materials and methods: the subgroup analysis was based on the data of COVID patients with known baseline IL-6 levels from the CORONA clinical study. Subgroups were formed according to baseline IL-6 levels: ≤5 pg/mL (normal) and >5 pg/mL (elevated). The subgroup analysis included descriptive statistics of the patients and time courses of their clinical and laboratory findings (at screening, on the day of investigational product administration, and further until day 14). In order to compare the percentages of patients who had required rescue therapy, the authors used Fisher's exact test. Results: the subgroup analysis included 91 patients (47 from the levilimab group and 44 from the placebo group). At baseline, the authors observed elevated levels of IL-6 in 31/47 (66%) subjects in the levilimab group and 29/44 (48.4%) subjects in the placebo group. The subjects with elevated IL-6 demonstrated more pronounced clinical signs of pneumonia and abnormalities in inflammatory markers. Elevated baseline IL-6 levels were associated with the need for rescue therapy (OR=3.714; 95% CI: 1.317–9.747; p =0.0183); this association was stronger in the placebo group (OR=8.889; 95% CI: 2.098–33.31; p =0.0036). Also, the placebo group showed long-term abnormalities in the clinical and laboratory findings. Conclusions: IL-6 is one of the key elements in the pathogenesis of cytokine release syndrome related to COVID-19 and other conditions. Elevated IL-6 levels are associated with the severity of COVID-19. Inhibition of IL-6 receptors by levilimab leads to clinical improvement in patients with severe COVID-19, suggesting the effectiveness of levilimab in pathogenesis-oriented therapy for cytokine release syndrome of other aetiologies." @default.
• W4313409546 created "2023-01-06" @default.
• W4313409546 creator A5016536735 @default.
• W4313409546 creator A5020011354 @default.
• W4313409546 creator A5023907058 @default.
• W4313409546 creator A5050216463 @default.
• W4313409546 creator A5059394775 @default.
• W4313409546 creator A5062468298 @default.
• W4313409546 creator A5071509889 @default.
• W4313409546 creator A5080554268 @default.
• W4313409546 creator A5083633233 @default.
• W4313409546 creator A5089142448 @default.
• W4313409546 creator A5090218998 @default.
• W4313409546 creator A5090816037 @default.
• W4313409546 date "2022-11-25" @default.
• W4313409546 modified "2023-09-27" @default.
• W4313409546 title "Levilimab clinical efficacy for interleukin-6 receptor inhibition in COVID-19 and its potential for treating cytokine release syndrome of other aetiologies" @default.
• W4313409546 cites W1979306238 @default.
• W4313409546 cites W1996815863 @default.
• W4313409546 cites W2023761225 @default.
• W4313409546 cites W2034357937 @default.
• W4313409546 cites W2076560655 @default.
• W4313409546 cites W2119473645 @default.
• W4313409546 cites W2130011407 @default.
• W4313409546 cites W2738799536 @default.
• W4313409546 cites W2796022095 @default.
• W4313409546 cites W2911371912 @default.
• W4313409546 cites W2942645055 @default.
• W4313409546 cites W2951829513 @default.
• W4313409546 cites W2952260713 @default.
• W4313409546 cites W3009314935 @default.
• W4313409546 cites W3009859788 @default.
• W4313409546 cites W3016538467 @default.
• W4313409546 cites W3016661132 @default.
• W4313409546 cites W3017621074 @default.
• W4313409546 cites W3025232850 @default.
• W4313409546 cites W3045153201 @default.
• W4313409546 cites W3048632747 @default.
• W4313409546 cites W3049325061 @default.
• W4313409546 cites W3080296106 @default.
• W4313409546 cites W3080981445 @default.
• W4313409546 cites W3088609942 @default.
• W4313409546 cites W3091975903 @default.
• W4313409546 cites W3093261446 @default.
• W4313409546 cites W3095757205 @default.
• W4313409546 cites W3123681476 @default.
• W4313409546 cites W3126231175 @default.
• W4313409546 cites W3130126061 @default.
• W4313409546 cites W3137250952 @default.
• W4313409546 cites W3138987278 @default.
• W4313409546 cites W3153931447 @default.
• W4313409546 cites W3157916142 @default.
• W4313409546 cites W3161594884 @default.
• W4313409546 cites W3162905796 @default.
• W4313409546 cites W3194630279 @default.
• W4313409546 cites W3196284155 @default.
• W4313409546 cites W3202642696 @default.
• W4313409546 cites W3202771662 @default.
• W4313409546 cites W3204335707 @default.
• W4313409546 cites W3210578089 @default.
• W4313409546 cites W4206449744 @default.
• W4313409546 cites W4210634883 @default.
• W4313409546 cites W4225262591 @default.
• W4313409546 doi "https://doi.org/10.30895/2221-996x-2022-22-4-446-459" @default.
• W4313409546 hasPublicationYear "2022" @default.
• W4313409546 type Work @default.
• W4313409546 citedByCount "0" @default.
• W4313409546 crossrefType "journal-article" @default.
• W4313409546 hasAuthorship W4313409546A5016536735 @default.
• W4313409546 hasAuthorship W4313409546A5020011354 @default.
• W4313409546 hasAuthorship W4313409546A5023907058 @default.
• W4313409546 hasAuthorship W4313409546A5050216463 @default.
• W4313409546 hasAuthorship W4313409546A5059394775 @default.
• W4313409546 hasAuthorship W4313409546A5062468298 @default.
• W4313409546 hasAuthorship W4313409546A5071509889 @default.
• W4313409546 hasAuthorship W4313409546A5080554268 @default.
• W4313409546 hasAuthorship W4313409546A5083633233 @default.
• W4313409546 hasAuthorship W4313409546A5089142448 @default.
• W4313409546 hasAuthorship W4313409546A5090218998 @default.
• W4313409546 hasAuthorship W4313409546A5090816037 @default.
• W4313409546 hasBestOaLocation W43134095461 @default.
• W4313409546 hasConcept C11988809 @default.
• W4313409546 hasConcept C126322002 @default.
• W4313409546 hasConcept C142724271 @default.
• W4313409546 hasConcept C187960798 @default.
• W4313409546 hasConcept C191093355 @default.
• W4313409546 hasConcept C203014093 @default.
• W4313409546 hasConcept C204787440 @default.
• W4313409546 hasConcept C27081682 @default.
• W4313409546 hasConcept C2777914695 @default.
• W4313409546 hasConcept C2778690821 @default.
• W4313409546 hasConcept C2779134260 @default.
• W4313409546 hasConcept C2780850621 @default.
• W4313409546 hasConcept C3008058167 @default.
• W4313409546 hasConcept C524204448 @default.
• W4313409546 hasConcept C535046627 @default.
• W4313409546 hasConcept C71924100 @default.
• W4313409546 hasConcept C74172505 @default.

• next